Drugs / ABT-869
Trials 17 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 110 trials | ||||||
| Phase 1 | NCT01506934 | Oct → Dec 2011 | — | Abbott | Terminated | No outcome recorded |
| Phase 1 | NCT01286974 | Aug 2011 → Aug 2012 | cancer | Abbott | Terminated | No outcome recorded |
| Phase 1 | NCT01413893 | Jun 2011 → Jun 2012 | cancer | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT01381341 | May → Dec 2011 | neoplasm | Abbott | Completed | No outcome recorded |
| Phase 1 | NCT01401933 | May → Oct 2011 | cancer | Abbott | Completed | No outcome recorded |
| Phase 1 | NCT01225302 | Sep 2010 → Jun 2012 | non-small cell lung carcinoma | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT01114191 | May 2010 → Feb 2011 | cancer | Abbott | Completed | No outcome recorded |
| Phase 1 | NCT00733187 | Feb 2009 → Jun 2012 | cancer | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT00754104 | Sep → Dec 2008 | cancer | Abbott | Withdrawn | No outcome recorded |
| Phase 1 | NCT00718380 | Sep 2008 → Jun 2012 | cancer | AbbVie | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03481842 | Oct 2021 | endometriosis of intestine, ovarian endometriosis | BioGene Pharmaceutical Ltd. | Withdrawn | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT01365910 | Jun 2011 → May 2012 | malignant colon neoplasm, rectal cancer | Vanderbilt-Ingram Cancer Center | Terminated | No outcome recorded |
| Phase 2 | NCT00716534 | Jun 2008 → Apr 2012 | non-small cell lung carcinoma | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT00517920 | Sep 2007 → Jun 2011 | hepatocellular carcinoma | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT00517790 | Aug 2007 → Jun 2011 | non-small cell lung carcinoma | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT00486538 | Jun 2007 → Jun 2011 | renal cell carcinoma | AbbVie | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01009593 | Jan 2010 → Jul 2012 | hepatocellular carcinoma | Abbott | Terminated | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00707889 Comparator | Oct 2008 → May 2012 | colon adenocarcinoma, rectum adenocarcinoma | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT00645177 Comparator | Jul 2008 → Dec 2009 | breast cancer | AbbVie | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 22 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABT-869 | “Linifanib (ABT-869) ATP-competitive VEGFR / PDGFR inhibitor for KDR, CSF-1R, Flt-1/3 and PDGFRβ - minimally sufficient therapeutic dose” NCT03481842 ↗ |
| Known as | linifanib | “This study assessed activity and safety of linifanib (ABT-869), a selective inhibitor of vascular endothelial growth factor and platelet-derived growth factor receptors, in...” PMID 21597387 ↗ Aug 201111“An Open-label, Randomized Phase 3 Study of the Efficacy and Tolerability of Linifanib (ABT-869) Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)” NCT01009593 ↗ “An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors.” PMID 22382879 ↗ Mar 2012 “Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer” PMID 22078932 ↗ Nov 2011 |
| Action | Inhibit | “a selective inhibitor of vascular endothelial growth factor and platelet-derived growth factor receptors” PMID 21597387 ↗ Aug 2011 |
| Route | Oral | “This open-label, multicentre, phase 2 trial of oral linifanib 0.25 mg/kg/day enrolled patients” PMID 22078932 ↗ Nov 2011 |
| Target | KDR | “Linifanib (ABT-869) ATP-competitive VEGFR / PDGFR inhibitor for KDR, CSF-1R, Flt-1/3 and PDGFRβ - minimally sufficient therapeutic dose” NCT03481842 ↗ |